Car-BDP Nanoparticles for Low-Power NIR Photodynamic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current photodynamic therapy (PDT) for deep-tissue cancers faces challenges due to weak absorption and low singlet oxygen quantum yield of existing NIR-light-activated molecules, limiting their effectiveness and safety, particularly with rare-earth components in inorganic nanoparticles raising toxicity concerns.
Innovation Solution
Development of biocompatible, carbazole-substituted BODIPY (Car-BDP) molecules encapsulated in biodegradable PLA-PEG-FA polymers to form NIR-absorbing nanoparticles that achieve high singlet oxygen quantum yield and deep-tissue penetration using low-power-density lamp light, enabling precise tumor targeting and imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inorganic UCNPs are used to enhance NIR absorption and singlet oxygen yield, then deep-tissue PDT effectiveness is improved, but physiological toxicity and systemic clearance issues arise due to rare-earth components
Solution Approach 1:
The patent changes the material composition parameters by replacing inorganic rare-earth UCNPs with organic photosensitizers containing BODIPY, cyanine, or porphyrin chromophores. These organic molecules are designed with specific structural modifications to achieve enhanced NIR absorption coefficients and high singlet oxygen quantum yields, thereby maintaining deep-tissue PDT effectiveness while eliminating the toxicity associated with rare-earth components.
Solution Approach 2:
The patent develops composite nanoparticle systems that combine organic photosensitizers with biocompatible carriers or encapsulation materials. These composite structures provide both the desired photodynamic therapy functionality through the organic chromophores and the biocompatibility, biodegradability, and controlled release properties needed to avoid the systemic clearance issues of inorganic nanoparticles.
2Reliability
If conventional visible light photosensitizers are used for PDT, then treatment effectiveness is achieved, but tissue penetration depth is limited
Solution Approach 1:
The patent modifies the optical absorption parameters of photosensitizers by designing organic molecules with extended conjugation systems and specific chromophore structures (BODIPY, cyanine, porphyrin) that shift their absorption maxima into the NIR region (650-900 nm). This parameter change enables deeper tissue penetration while maintaining high singlet oxygen generation efficiency for effective PDT treatment.
3Reliability
If high-power laser beams are used to activate photosensitizers in deep tissue, then therapeutic outcome is improved, but equipment cost and operational complexity increase
Solution Approach 1:
The patent changes the photosensitizer activation parameters by developing organic molecules with extremely high absorption coefficients in the NIR region. This allows the use of low-power, incoherent light sources such as halogen lamps or LED arrays instead of high-power lasers, thereby achieving the same therapeutic outcome with simpler, more cost-effective equipment while maintaining deep-tissue penetration capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Car-BDP nanoparticles demonstrate exceptional deep-tissue tumor targeting and therapeutic efficacy with high singlet oxygen yield, low cytotoxicity, and excellent photostability, providing a cost-effective and biocompatible solution for PDT, while allowing simultaneous in vivo imaging.
Implementation Method 1
The mechanism of PDT is based on the interaction between the excited photosensitizer and the surrounding molecules, which generates reactive oxygen species (ROS), such as singlet oxygen
Implementation Method 2
After being encapsulated with biodegradable PLA-PEG-FA polymers, Car-BDP can form uniform, water-soluble and tumor-targeting small organic nanoparticles
Data Source
Figure 1~1b
Figure 2~2a
Figure 3~4b
AI summary
The invention provides a novel class of NIR-absorbing biocompatible organic nanoparticles for effective imaging, targeting and treatment of deep-tissue cancers or tumors. The invention enables a new platform for precise cancer- or tumor-targeting theranostics and clinical cancer treatment.